Clinical Trial Search

Primary: Mean Difference in Change in Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) Score at Baseline and 6 Weeks. — -0.9; -5.78; 3.52; -7.26 Units on a scale

Primary: Change in Vasoreactivity During Exercise at Baseline and 8-week Visits. — 0.031; 0.028 cm s-1 mmHg-1/mmHg CO2

Primary: Time (in Days) to Recovery — 13; 17 Days

Primary: The Feasibility of Inpatient Bedside Neurocognitive Testing of Pediatric Patients With Minor Traumatic Brain Injury. — 120 participants

Primary: Change in Concussive Symptoms on the Post Concussion Symptom Scale — 9 units on a scale

Primary: Post Traumatic Growth — 41.7; 57.8; 40.4; 60.7 Score on a scale

Primary: Performance on Multiple Sleep Latency Test (MSLT) — 6.67; 7.32; 6.73; 7.88 minutes

Primary: Incidence of RGn550's Adverse Device Effects (ADEs) — 10; 10 Participants

Primary: Time (in Days) That a Patient Reports Symptoms From Their Concussion. — 7.3; 4.5 Days Symptomatic — p=.42

Primary: Post-Intervation Post-concussion Symptom Scores Using RPQ - Intent to Treat — 3.5; 5.1; 4.2; 3.5 units on a scale

Primary: Change In SDNN — 43.; 21.87; 19.4 ms

Primary: A Measure Assessing the Sensitivity and Specificity Rate Based on the Nautilus Neurowave Data — 77; 87 percentage of participants

Primary: Impact ( Immediate Post-concussion Assessment and Cognitive Testing) Healthy Athlete — 86.33; 84.0; 90.73; 89.1436 score on Immediate post concussion scale — p=0.0003

Primary: Sleep Quality - Pittsburgh Sleep Quality Index (PSQI) — 1.28; 1.35 score on a scale

Primary: MRI Image Data Sets — 79; 150; 290; 111 Images collected

Primary: Participant Compliance With HeadOn Program — 45; 5 Participants

Primary: Symptom Management - Post Concussion Symptom Scale — 44; 71; 39; 51 score on a scale

Primary: Examiner Score — 0.617; 0.907; 0.865; 1.155 score on a scale

Primary: Number of Participants Undergoing Acoustic Reflectance — 410; 410 participants — p=<0.05

Primary: Number of Headache Days — 4; 3; 3; 4 number of headache days

Primary: NeuroCom Computerized Dynamic Posturography Sensory Organization Test (SOT) — 42.77; 36.24; 63.73; 62.00 score on a scale — p=0.41

Primary: Reaction Time Difference Between Drug and Placebo Groups — 2.44; 2.49; 2.52; 2.48 log(milliseconds) — p=0.871

Primary: Summary of Treatment-Emergent Adverse Events — 13; 5; 5; 3 Participants

Primary: Number of Headache Days Per Week — 4.2; 4.6; 3.1; 4.3 days/week — p=<0.000

Primary: Pre-season to Post-season DTI Percentage Change — -0.17; -1.27; 0.45; 2.83 percentage of change

Primary: Safety of Higher Dosage of DHA — 0; 1 Participants

Primary: Peripheral Vestibular Function (Vestibulo-ocular Reflex/Semicircular Canal): Caloric Weakness — 8.8; 14.7; 12.3; 7.1 percentage of caloric weakness

Primary: Longitudinal DTI Changes — 0.000809; 0.000760; 0.000763; 0.000843 voxels

Primary: Number of Days to Return to Full Unrestricted Athletic Participation — 11.0; 11.9 Days

Primary: Number of Participants Who Scored Above the Midpoint on Each Subscale of the Credibility and Expectancy Questionnaire (CEQ) — 21; 23; 16; 19 Participants